RecruitingPhase 1NCT06863480

Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events

THRIVE: Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events

Sponsor

University of Florida

Enrollment

30 participants

Start Date

Mar 2, 2026

Study Type

INTERVENTIONAL

Conditions

Delayed Cerebral Ischemia Aneurysmal Subarachnoid Hemorrhage

Summary

In this study, tocilizumab-aazg (TYENNE) will be administered to see whether tocilizumab-aazg is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.

Eligibility

Min Age: 18 YearsMax Age: 89 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called tocilizumab-aazg (TYENNE) for people with aneurysmal subarachnoid hemorrhage and delayed cerebral ischemia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 89 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.